Result Update: ICICI Bank, Ranbaxy, Cipla, Wockhardt, United Phosphorus

ICICI Bank Q4 (cr - crore, vs - versus) -Net Profit down 35.29% from Rs 1149.8 cr to Rs 744 cr ((Estimates: Rs 841.03 cr)) -NII down 2.89% from Rs 2079.46 cr to Rs 2139 cr ((Estimates: Rs 1987.76 cr)) -NIM at 2.6%; Non-interest income down 29.13 % to Rs 1,674 crore -Treasury income of Rs 214 cr vs Rs 164 cr ; fee income declined by 30.34% -Provisions up 14.46% from Rs 1007.7 cr to Rs 1084.54 cr -Other Income down 29.31% from Rs 2361.65 cr to Rs 1673.67 cr

Ranbaxy Q1CY09 YoY: -Net sales up 9% at Rs 1558 cr vs Rs 1613.7 cr ((Estimates Rs 1766 Cr)) -Net Loss of Rs 760 cr vs net profit of Rs 136.80 cr ((higher than any brokerage estimate, which ranged between loss of Rs 9 crore to Rs 230 crore)) -Forex loss of Rs 918 cr due to forex derivative option position of $1.4 billion

Ranbaxy Guidance for CY09: -Sales of Rs 7000 crore in sales ((lower than CY08 sales of Rs 7241 cr)) -Net loss of Rs 800 crore -Guidance takes into account loss of Q1; rest of the quarters will be breakeven quarters -Dollar – Rupees rate is estimated at 50.50 for Guidance

Cipla Q4 standalone (YoY): -Net Sales at Rs 1235.2 Cr Vs Rs 1,122.1 Cr -Net Profit at Rs 252.9 Cr Vs Rs 179.5 Cr -Other Operating Income of Rs 131 Cr, includes tech, licensing income -Outstanding forex contracts down to $123 million

Wockhardt Q1 CY09 consolidated YoY: -Net sales up 11% at Rs 869.4 cr vs Rs 785.7 cr -OPM 18% vs 22% -Net loss at Rs 20.2 crore vs profit Rs 50.9 cr -Premium on FCCB at Rs 14 cr -Interest costs at Rs 113 cr doubled from last year -Wockhardt board approves transfer of animal healthcare business to subsidiary

United Phosphorus FY09 YoY: -Revenues up 32% to Rs 4931.6 cr vs Rs 3730.58 cr
-OPM at 19.2% vs 18.9% -PAT up 80% to Rs 465.13 cr vs Rs 258.89 cr -APAT up 73% to Rs 485.08 cr vs Rs 281.07 cr

Balrampur Chini Q2: -Net Profit At Rs 66.2 Cr Vs Rs 65.65 Cr -Net Sales At Rs 355 Cr Vs Rs 308.03 Cr

Infotech Ent Q3 Consolidated (QoQ): Net Sales: Rs 235 cr vs Rs 232.7 cr Operating Profit: Rs 50.9 cr vs Rs 45 cr Net Profit: Rs 18.5 cr vs Rs 14.5 cr

Strides Arcolab Q4 Consolidated: Net Sales: Rs 284.2 cr vs Rs 207 cr Operating Profit: Rs 42.4 cr vs Rs 13.3 cr Net Profit: Rs 10.5 cr vs Rs 52.5 cr Other Income: Nil vs Rs 71.2 cr

Andhra Sugar Q4: Net Sales: Rs 145.6 cr vs Rs 108 cr Operating Profit: Rs 37.6 cr vs Rs 27.7 cr Other Loss of Rs 6.3 cr vs Other Income: Rs 4.6 cr Net Profit: Rs 9.45 cr vs Rs 12.3 cr

Pantaloon Q3: Net Sales: Rs 1642 cr vs Rs 1354.4 cr Operating Profit: Rs 173 cr vs Rs 114.1 cr Interest Costs: Rs 84.7 cr vs Rs 42.9 cr Net Profit: Rs 34.4 cr vs Rs 32.1 cr

3i Infotech Q4 (QoQ): Net Sales: Rs 606.7 cr vs Rs 608.8 cr Operating Profit: Rs 119 cr vs Rs 110 cr Net Profit: Rs 90.5 cr vs Rs 64.5 cr 3i Infotech okays merger of 4 arms with itself

Piramal Life Q4 (QoQ) (Piramal R&D Arm) Net Sales: Rs 56 lakh vs Rs 1.6 cr
Net Loss of Rs 37.4 cr vs Rs 25.9 cr

Granules India Q3 Consolidated Net Sales: Rs 96.6 cr vs Rs 98.1 cr Net Profit: Rs 20 lakh vs Rs 50 lakh

Micro Inks Q1: Net Sales: Rs 297.8 cr vs Rs 321.9 cr Net Profit: Rs 19 cr vs Rs 29.5 cr

Techno Electric and Engg Q4: Net Sales: Rs 117.1 cr vs Rs 148 cr Net Profit: Rs 19.5 cr vs Rs 20.6 cr